Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully completed negotiations for Itovebi® (inavolisib), a targeted treatment f…

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that it successfully completed negotiations with the ...

Gazyva® (obinutuzumab) receives positive reimbursement recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) for persons wi…

Hoffmann-La Roche Limited (Roche Canada) is pleased to share that on June 3, 2026, the Institut national d'excellence en ...

F. Hoffmann-La Roche Ltd: FDA grants Priority Review to Roche's Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vi ...
Nature

Hoffmann-La Roche Ltd.

No articles found. Hoffmann-La Roche Ltd. did not contribute to any primary research papers from Nature Index journals in the current 12 month window. The following affiliated institutions are wholly ...
Los Angeles Times

Roche Group Returns to Its Roots

Century-old Swiss drug giant Roche Group, the parent of Hoffmann-La Roche, is returning to its roots and, potentially, its glory days. Early on, the Basel-based pharmaceutical company made a variety ...
BioWorld

Roche divulges new SIK1, SIK2 and SIK3 inhibitors

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized benzimidazole derivatives acting as serine/threonine-protein kinase SIK2 (QIK) and/or SIK1 (SNF1LK) and/or SIK3 ...
Law

Genentech, Biogen and Hoffmann-La Roche File Lawsuit Over Planned Release of 'Copycat' of Pioneering Cancer Drug

Global pharmaceutical companies Genentech, Biogen and Hoffmann-La Roche filed a patent infringement lawsuit against Dr. Reddy's Laboratories in federal court Friday alleging the defendants plan to ...
Finanznachrichten

F. Hoffmann-La Roche Ltd: Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys plasma phosphorylated-tau 217 (pTau217)

Elecsys pTau217 is the first blood test for Alzheimer's disease pathology with a single-assay design, intended to rule in and rule out amyloid pathology across primary and secondary care, offering ...